Sudden sensorineural hearing loss strikes without warning, typically in one ear, and is formally defined as a drop of at least 30 decibels across three connected frequencies within 72 hours. About half of people who experience it recover fully, usually within a couple of weeks, but the other half are left with some degree of permanent hearing change. Because the window for effective treatment is narrow and the condition is often mistaken for something minor like earwax or allergies, understanding what is happening and how quickly to act can make a real difference in outcome.
What It Feels Like and How It Shows Up
Most people notice something is wrong the moment they wake up or when they try to use a phone on the affected side. The hearing loss is almost always one-sided and can range from mild muffling to near-total deafness in that ear. Tinnitus is the most common companion symptom, showing up in more than half of cases. Some people also feel a sense of fullness in the ear, as if it needs to pop. Vertigo or dizziness appears in a smaller fraction of patients and tends to signal a more severe episode.
A meta-analysis of over 4,800 patients found that those who experienced vertigo alongside their hearing loss had worse hearing recovery compared to those without dizziness. Interestingly, that disadvantage seemed to shrink when steroid injections were given directly into the middle ear, though the authors noted more research is needed to confirm that pattern. Tinnitus and ear fullness, by contrast, did not independently predict worse outcomes in studies that controlled for other factors.
Why It Happens
In the majority of cases, doctors never pin down a specific cause. That makes the condition “idiopathic,” which is medical shorthand for “we’re not sure.” The leading theories fall into three buckets: viral infection, blood-supply disruption, and immune-system attack. These are not mutually exclusive, and some cases probably involve more than one mechanism at once.
Viral Infections
The viral theory has been around for decades. An early serological study of 77 patients with sudden hearing loss found significant antibody changes to at least one virus in about 65% of cases, and many patients showed reactions to multiple viruses at once. Animal studies have shown that herpes simplex virus can directly damage the delicate structures of the inner ear, destroying outer hair cells and causing scarring. When infected animals were treated with antivirals and steroids, the damage was less severe. The tissue changes in those animals closely resembled what pathologists see in human temporal bones from patients who lost their hearing suddenly. Still, proving that a virus directly caused a given person’s hearing loss remains difficult. The link between herpes simplex infection and hearing impairment in humans is plausible but still considered hypothetical in terms of a firm causal chain.
Vascular Problems
The inner ear is supplied by a single small artery with no backup circulation. If blood flow through that artery is disrupted even briefly, the oxygen-hungry hair cells and nerve structures can suffer permanent damage. This vascular theory draws strength from the way sudden hearing loss resembles a stroke or heart attack in its abrupt, one-sided onset. Researchers have explored whether small vessel disease in the brain might also affect the tiny vessels feeding the inner ear. One study found that reduced blood flow from small vessel disease could damage the hair cells and neural structures responsible for hearing. Whether the cause is a tiny clot, a spasm, or a broader pattern of blood pressure instability, the end result is the same: the cochlea doesn’t get enough oxygen.
Autoimmune Reactions
The immune system occasionally turns on the inner ear. Antibodies that normally fight infection may instead target proteins found in cochlear tissue, triggering inflammation and damage. Conditions like lupus, rheumatoid arthritis, and Sjögren’s syndrome have been linked to sensorineural hearing loss. In one study of 694 patients with sudden hearing loss, about 6% were eventually diagnosed with autoimmune inner ear disease, and most of those had the primary form where the immune attack is directed specifically at the ear rather than being part of a wider systemic disease. The autoimmune theory is especially relevant in bilateral cases, which we’ll get to shortly.
Who Is at Higher Risk
Sudden hearing loss can strike anyone, but certain cardiovascular risk factors appear more often in people who develop it. A systematic review and meta-analysis found that patients with sudden hearing loss were significantly more likely to have diabetes and high blood pressure compared to matched controls. Total cholesterol was also elevated in the hearing-loss group by a meaningful margin. A separate pooled analysis found significantly increased risk for people with high triglycerides and high total cholesterol, though the picture for blood pressure and diabetes was less clear-cut once studies adjusted for other variables. The inconsistency between these two meta-analyses is worth noting: individual cardiovascular risk factors show up repeatedly in the research, but their exact contribution probably varies from person to person. The broader takeaway is that anything that compromises small-vessel blood flow may put the inner ear at risk.
Getting Diagnosed Quickly
The single most important thing to know about sudden hearing loss is that it is a medical urgency. Many people assume a plugged ear will clear on its own, and that delay can cost them hearing. The standard workup starts with an audiogram, the basic hearing test, which confirms the pattern and severity of loss. A tuning fork or simple bedside test can help distinguish sensorineural loss (inner ear or nerve problem) from conductive loss (middle ear or eardrum problem), but the audiogram provides the definitive numbers.
Beyond the audiogram, imaging matters. An MRI is recommended for all patients initially diagnosed with sudden hearing loss because a small percentage turn out to have an acoustic neuroma, a benign tumor on the hearing nerve. Hearing recovery after steroid treatment does not rule out a tumor; patients whose hearing improved still turned out to have acoustic neuromas in some cases. The MRI catches these and prevents a delayed diagnosis that could have more serious consequences down the line.
Blood work typically screens for the conditions that could be driving the hearing loss: blood sugar, cholesterol, inflammatory markers, thyroid function, and sometimes autoimmune panels. If vertigo is prominent, vestibular testing can help determine whether the balance organs are also involved.
Treatment and the Steroid Question
Corticosteroids are the backbone of treatment. Oral prednisone is the most common first-line therapy, typically started as soon as possible and tapered over one to two weeks. The logic is that steroids reduce inflammation in the inner ear, and since inflammation is a common thread across viral, vascular, and autoimmune causes, they address multiple possible mechanisms at once.
A natural question is whether higher steroid doses work better. A trial published in NEJM Evidence compared high-dose prednisone and high-dose dexamethasone against a standard lower-dose prednisone regimen. The high-dose groups did not show better hearing recovery, and they experienced more medication-related side effects. An earlier study had suggested that high-dose oral dexamethasone might improve recovery compared to standard prednisone, but the larger, more rigorous trial did not confirm that advantage. The current consensus leans toward standard dosing rather than aggressive high-dose protocols.
When oral steroids do not produce adequate improvement, or when someone cannot tolerate systemic steroids, injections directly through the eardrum into the middle ear are the main alternative. A randomized trial comparing oral prednisone to intratympanic methylprednisolone found that the injection approach was not inferior: the oral group improved by about 31 decibels and the injection group by about 29 decibels at two months, a difference well within the margin that the study defined as clinically equivalent. A systematic review of the broader literature came to a similar conclusion: intratympanic steroids performed comparably to oral steroids as initial therapy and showed consistent benefit as “salvage” therapy for patients who did not respond to the first round of oral treatment.
Hyperbaric oxygen therapy is sometimes offered as an add-on, particularly in countries where it is more widely available. The idea is that breathing pure oxygen under pressure raises oxygen levels in the inner ear, counteracting the hypoxia that may be driving the damage. It has also been proposed to reduce blood viscosity and calm inflammation. The evidence is mixed enough that it is not a standard recommendation everywhere, but some treatment protocols include it alongside steroids, especially for severe cases.
What Predicts Recovery
Not everyone responds to treatment equally, and several factors tilt the odds. The severity of the initial hearing loss is one of the strongest predictors. Patients whose audiograms show a loss greater than about 50 to 60 decibels tend to recover less hearing even with prompt treatment, often gaining back no more than 20 to 30 decibels. More severe initial loss suggests more extensive damage to the inner ear structures.
The shape of the hearing loss on the audiogram also matters. Research using machine learning to analyze prognostic factors found that ascending patterns (where high frequencies are worse than low) and flat or U-shaped losses carried a more favorable outlook. Descending patterns, where the higher frequencies are hit hardest, and profound across-the-board loss both predicted worse outcomes. The likely explanation involves the anatomy of the cochlea: the base of the cochlea, which handles high-frequency sound, has higher metabolic demands and a blood supply arrangement that may make it more vulnerable to lasting damage.
Timing of treatment is another consistent finding. Patients who start steroids earlier tend to do better, though one study found no measurable difference between starting within 24 hours versus starting within seven days. Still, most clinicians treat the condition as time-sensitive, and waiting weeks clearly reduces the chances of meaningful recovery.
Vertigo at onset, as mentioned earlier, tends to signal worse outcomes. Age and whether the loss is bilateral also play a role, with older patients and those with both ears affected generally facing a harder road.
The Psychological Toll
Sudden hearing loss does not just affect hearing. Losing the ability to hear normally in one ear overnight is a jarring, disorienting experience, and the emotional fallout can be significant. A study comparing patients with sudden one-sided hearing loss to healthy controls found dramatically higher anxiety, depression, and hopelessness scores in the patient group. The differences were large and statistically clear.
Even after the acute phase resolves, people left with permanent single-sided deafness face ongoing challenges. Research into the psychological and social consequences of single-sided deafness found a range of difficulties: trouble following conversations in noisy environments, reduced awareness of where sounds are coming from, worry about losing hearing in the remaining ear, embarrassment related to the social stigma of hearing loss, and diminished confidence in everyday social situations. These effects are easy to underestimate from the outside, especially since the person looks perfectly healthy.
When Both Ears Are Affected
Bilateral sudden hearing loss is rare but considerably more serious than the unilateral form. A review of the literature found that bilateral cases are more often linked to toxic exposures, autoimmune conditions, tumors, or vascular events. The age of onset follows a different pattern, with a bimodal distribution compared to the single peak seen in unilateral cases. Hearing loss tends to be more profound, and recovery is poorer. The review also reported a 35% mortality rate in bilateral cases, reflecting the fact that the underlying causes are often systemic and serious.
The autoimmune connection is especially pronounced in bilateral presentations. In one comparison, autoimmune diseases were found in 36% of patients with simultaneous bilateral sudden hearing loss, compared to far fewer in unilateral cases. Positive antinuclear antibody testing was present in half of the bilateral group versus only about 8% of unilateral patients. When both ears go at once, clinicians tend to pursue autoimmune workups more aggressively.
Children and Sudden Hearing Loss
Sudden hearing loss in children is less common than in adults but presents unique diagnostic challenges. Young children may not be able to articulate what has happened, and the standard audiogram requires a level of cooperation that toddlers and preschoolers cannot always provide. Alternative testing methods like play audiometry, visual reinforcement audiometry, or auditory brainstem response testing (sometimes under sedation) are used to pin down the diagnosis.
A case series of 20 pediatric patients found an average age of about 11 years at presentation. Only 30% of the children were seen within the first two weeks of symptom onset, which is a much longer delay than typical in adults. Tinnitus was the most common associated symptom at 55%, followed by ear pain and vertigo. Bilateral involvement was more common in children than is typical in the adult literature, and profound hearing loss was the most frequent severity level at 45%. These patterns suggest that pediatric cases may go unrecognized longer and may present with more severe loss by the time they reach a specialist.
Long-Term Options When Hearing Does Not Return
For people whose hearing does not recover after treatment, the question shifts from “will it come back?” to “what can I do about it?” Traditional options for single-sided deafness include CROS hearing aids, which pick up sound on the deaf side and route it to the hearing ear, and bone-anchored devices that work on a similar principle through vibration. These help with awareness of sound from the affected side but do not restore true binaural hearing.
Cochlear implantation has emerged as a more aggressive option for unilateral deafness after sudden hearing loss. A meta-analysis and systematic review found that implantation improved tinnitus, speech comprehension in noise, and the subjective sense of sound localization. All patients in the reviewed studies felt they could localize sound better, and most reported better speech understanding. A more recent study confirmed significant improvements across speech, spatial hearing, overall hearing handicap, tinnitus severity, and general quality of life after cochlear implantation for single-sided deafness. The gains in speech perception under implant-only conditions were especially large.
The decision to pursue a cochlear implant for one-sided deafness is not straightforward. The surgery is invasive, the device requires ongoing maintenance and mapping adjustments, and the quality of sound through an implant is fundamentally different from natural hearing. Duration of deafness before implantation also appears to influence outcomes, with shorter durations generally associated with better results. But for people who are struggling with the functional and psychological consequences of permanent single-sided deafness, it represents a meaningful option that was not widely available even a decade ago.
Emerging Research on Biomarkers
One of the frustrations with sudden hearing loss is that diagnosis still relies almost entirely on the audiogram and the patient’s history. There are no blood tests or imaging findings that confirm the condition or reliably point to the underlying cause in most cases. Researchers have been exploring whether microRNAs, small molecules that regulate gene activity and are stable enough to measure in blood, could serve as noninvasive biomarkers for acquired sensorineural hearing loss. The idea is appealing: a blood draw at the time of diagnosis could theoretically help identify the mechanism at work (viral, vascular, or autoimmune) and guide treatment more precisely. This research is still in its early stages, though, and no validated clinical biomarker has made it into routine practice yet.
For now, the practical reality is that treatment for sudden hearing loss remains empiric. Steroids are given because they address inflammation broadly, not because a test confirmed inflammation as the specific cause. A reliable biomarker would change how clinicians approach the condition, potentially allowing them to tailor therapy to the individual rather than applying the same protocol to everyone. Whether microRNAs or some other molecular signal will eventually fill that role is an open question, but it is one of the more promising directions in the field.